Abstract
The Dopamine Hypothesis has been the leading theory used to explain the mechanism of the clinical manifestation of schizophrenia symptoms for decades. It is unclear if excess dopaminergic activity is the primary pathophysiology causing psychosis or if this dopamine excess is triggered by upstream, downstream or neurodevelopmental abnormalities. A corollary hypothesis suggests that the glutamatergic system may be involved in the pathogenesis of schizophrenia, and that dysfunction of the glutamate system may actually lead to dopamine excess. The NMDA Receptor Hypofunction Hypothesis suggests that malfunctioning NMDA receptors may be the cause for the theoretically hypofunctioning glutamate system. This paper seeks to describe and discuss the potential underlying genetic vulnerabilities of the NMDA receptor and how aberrant genes coding for this receptor may lead to schizophrenia symptoms.
Keywords: NMDA receptor, schizophrenia, glutamate, genetics, Dopamine Hypothesis, neurodevelopmental abnormalities, ion channel, homeostasis, psychosis, psychiatric symptoms
Current Pharmaceutical Design
Title:Genetic Data Supporting the NMDA Glutamate Receptor Hypothesis for Schizophrenia
Volume: 18 Issue: 12
Author(s): Thomas L. Schwartz, Shilpa Sachdeva, Stephen M. Stahl
Affiliation:
Keywords: NMDA receptor, schizophrenia, glutamate, genetics, Dopamine Hypothesis, neurodevelopmental abnormalities, ion channel, homeostasis, psychosis, psychiatric symptoms
Abstract: The Dopamine Hypothesis has been the leading theory used to explain the mechanism of the clinical manifestation of schizophrenia symptoms for decades. It is unclear if excess dopaminergic activity is the primary pathophysiology causing psychosis or if this dopamine excess is triggered by upstream, downstream or neurodevelopmental abnormalities. A corollary hypothesis suggests that the glutamatergic system may be involved in the pathogenesis of schizophrenia, and that dysfunction of the glutamate system may actually lead to dopamine excess. The NMDA Receptor Hypofunction Hypothesis suggests that malfunctioning NMDA receptors may be the cause for the theoretically hypofunctioning glutamate system. This paper seeks to describe and discuss the potential underlying genetic vulnerabilities of the NMDA receptor and how aberrant genes coding for this receptor may lead to schizophrenia symptoms.
Export Options
About this article
Cite this article as:
Thomas L. Schwartz, Shilpa Sachdeva, Stephen M. Stahl , Genetic Data Supporting the NMDA Glutamate Receptor Hypothesis for Schizophrenia , Current Pharmaceutical Design 2012; 18 (12) . https://dx.doi.org/10.2174/138161212799958594
DOI https://dx.doi.org/10.2174/138161212799958594 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
TMS - A New Neuroimaging Combinational Tool to Study Brain Function
Current Medical Imaging FDG-PET in the Evaluation of Brain Metabolic Changes Induced by Cognitive Stimulation in aMCI Subjects
Current Radiopharmaceuticals A New Target for Diagnosis and Treatment of CNS Disorders: Agmatinergic System
Current Medicinal Chemistry Planar Cell Polarity Signaling in Collective Cell Movements During Morphogenesis and Disease
Current Genomics Physiologic Responses in Anxiety
Current Psychiatry Reviews Association Between Seizures and Diabetes Mellitus: A Comprehensive Review of Literature
Current Diabetes Reviews Stimulating Effects of H1-Antagonists
Current Pharmaceutical Design On Some Physiological Aspects of Ethanol Repercussion on Neural and Cardiorenal Functions
Central Nervous System Agents in Medicinal Chemistry The Role of Ionotropic Glutamate Receptors in Childhood Neurodevelopmental Disorders: Autism Spectrum Disorders and Fragile X Syndrome
Current Neuropharmacology Nanomedicines for Brain Targeting: A Patent Review
Recent Patents on Nanomedicine HSV-1-Derived Recombinant and Amplicon Vectors for Gene Transfer and Gene Therapy
Current Gene Therapy Cingulate Volume Abnormalities in Emerging Psychosis
Current Pharmaceutical Design Pharmacological Targeting of Neuronal Kv7.2/3 Channels: A Focus on Chemotypes and Receptor Sites
Current Medicinal Chemistry Cannabinoids for the Treatment of Schizophrenia: An Overview
Current Topics in Medicinal Chemistry Endogenous Cannabinoid and Opioid Systems and their Role in Nicotine Addiction
Current Drug Targets The Physiological Basis of Respiratory Sensation
Current Respiratory Medicine Reviews Silencing the Brain May be Better than Stimulating it. The GABA Effect
Current Pharmaceutical Design Atypical Neuroleptic Malignant Syndrome or Serotonin Toxicity Associated with Atypical Antipsychotics?
Current Drug Safety Possible Involvement of Muscarinic Receptors in Psychiatric Disorders: A Focus on Schizophrenia and Mood Disorders
Current Molecular Medicine Peptides as Signaling Inhibitors for Mammalian MAP Kinase Cascades
Current Pharmaceutical Design